Home > Insider Trading > Filing (0000899243-19-003668)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597553	Sage Therapeutics Inc.	SAGE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192603	P Kevin Starr	C/O Sage Therapeutics, Inc., 215 First Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-02-12	0	$0.00	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	302,817	Direct

Footnotes

On February 12, 2019, Third Rock Ventures II, L.P. ("TRV II") sold 37,362 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $153.60 to $154.51, inclusive, at a weighted average price per share of $154.2096. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Following the reported transaction, TRV II held zero shares of Common Stock of the Issuer.
These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin, Kevin Starr ("Starr") and Dr. Robert Tepper. Due to an ethical wall between Mr. Starr and each of TRV II, TRV GP II and TRV GP II LLC that prevents (i) the sharing of information related to the Issuer between Mr. Starr and the foregoing funds and their respective representatives and (ii) participation in investment decisions with respect to the common stock of the Issuer held by TRV II, Starr disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.